While each of this week's three innovators has years of experience under their belts, they are each starting something new. Courtesy photos

Common ingredients among entrepreneurs is a great idea, plenty of hard work, and a whole lot of luck. And, if they are lucky, they've got some experience under their belts too. These three innovators this week are all in the process of starting something — a venture fund, an app, an investment platform — but lucky for them, they know what they're doing.

Allison Lami Sawyer, partner at The League of Worthwhile Ventures

Courtesy of Allison Lami Sawer

Allison Lami Sawyer's story has stuck with me since I first heard it a few weeks ago. Primarily because she's a fantastic storyteller paired with, well, a great story. She's from Alabama and didn't really meet a female entrepreneur until she was one. She started Rebellion Photonics and ran it for several years before recently leaving to start something new: a seed fund called The League of Worthwhile Ventures. Sawyer isn't afraid to start something new and cherishes her role inspiring or advising other women entrepreneurs by being a role model for innovation — something she didn't have as a kid. Read the full story here.

Chris Staffel, COO at Patients We Share

Courtesy of Chris Staffel

While relatively new to the health care business, Chris Staffel has tons of business experience from both coasts. She brings those skills to Patients We Share, an app aiming to enhance and improve doctor referrals. The idea originated from two doctors here in Houston, but as it started to take off, they invested in business professionals like Staffel to make their dream a reality. Read the full story here.

Rashad Kurbanov, CEO and co-founder of iownit.us

Courtesy of iownit.us

I'm bending the rules a little bit here because, unfortunately, Houston cannot claim Rashad Kurbanov. However, the New Yorker is betting on Houston for his new company, iownit.us. The website is a platform for private securities investors and fund-raising companies to connect and make deals — without any red tape. Kurbanov has years of financial experience, but has never done anything like this before because well, no one has. Read the full story here.

These three entrepreneurs didn't see their careers coming. Courtesy photos

3 Houston innovators to know this week

Who's Who

The career paths of startup or innovation leaders isn't usually a direct path. All three of this week's innovators to know took a roundabout way to their current gigs, which included a leap of faith or two for each of them. If their winding careers are any indication, they've got more exciting leadership ahead.

Youngro Lee, CEO and co-founder of NextSeed

Courtesy of NextSeed

Starting off on Wall Street as a private equity lawyer, Youngro Lee knows money. And he knew when the Jobs Act went into effect several years ago, there was a huge opportunity for companies to raise money from non-accredited individual investors, rather than just the super wealthy private investors. He left his legal career to leverage this new law to start NextSeed, which is a platform for businesses to raise capital for from anybody. Read more here.

Jane Henry, founder and CEO of SeeHerWork

Courtesy of SeeHerWork

Jane Henry watched as her glove flew right off her hand when she was cleaning up after Hurricane Harvey — her house got three feet of mud, and she got the idea for her company. SeeHerWork goes above and beyond the normal "pink it and shrink it" approach to women's workwear. Henry wants to see female workers with better fitting safety gear. Read more here.

Erik Halvorsen, director of the TMC Innovation Institute

Courtesy of TMC

As a kid, Erik Halvorsen wanted to be a doctor — he even took the MCAT and was on track for med school. He decided to look into other avenues that combined his passion for medicine and his entrepreneurial spirit. As director of TMCx, he helps innovative medical technologies become standard practice in hospitals. Read more here.

Editor's note: Halvorsen reportedly left his position at TMC on December 13, 2018.

Armed with their doctorate degrees and startups, these three STEM biotech innovators are going places. Courtesy photos

3 Houston heath tech innovators to know this week

Who's Who

Whether it's for dogs or dating, Houston is prime for innovative leaders in health science startups, and there are three in particular you need to know going into a new week. From a DNA-based dating app creator and a researcher curing cancer in dogs to cutting-edge biotech leader, here are the Houston innovators to know. Doctorate degrees and startup companies in hand, each of these entrepreneurs is going places.

Brittany Barreto, co-founder and CEO of Pheramor

Courtesy of Pheramor

Brittany Barreto was studying genetics in college, and her professor was talking about how there are 11 genes in DNA that can determine physical compatibility with others. She had the idea right then and there in the classroom to make a DNA-based dating app. Almost 10 years later, she's done it, with Pheramor.

The Houston startup has launched nationwide and is in the midst of another capital campaign. Barreto is also looking to expand her team to account for the growth and success.

Lidong Qin, founder of Innovative Biochips

Courtesy of Lidong Qin

Lidong Qin spends his days as a professor at the Houston Methodist Research Institute's department of nanomedicine, but three years ago, he expanded his resume. He launched his biotech startup, Innovative Biochips, as an independent faculty startup that licensed technology from Houston Methodist.

Qin says it can be difficult to launch a biotech startup in Houston, since the industry requires hefty initial funds to open a facility, get patents and hire a team of researchers. Now, iBiochips is armed with private investments and a $1.5 million grant from the National Institutes of Health's Small Business Technology Transfer program to continue researching and developing early disease detection technologies.

Colleen O'Connor, founder of CAVU Biotherapies 

CAVU Colleen O'Connor

Courtesy of CAVU Biotherapies

Losing a pet is awful, and for so many people, pets are full-blown family members. When Colleen O'Connor lost her furry family members to cancer, she knew she had to do something about it. Cancer treatment in humans had evolved to include immunotherapy, and O'Connor thought man's best friend deserved an upgrade from the 1980s practices veterinarians use.

She created Houston-based CAVU Biotherapies, and, in September, the first treatment was administered to a black lab named Franklin. O'Connor is focused on expanding her treatment and its access to pups so that no pet owner has to prematurely say goodbye to good boys and girls.

From smart pillboxes to innovation incubators, here are three people you need to know this week in innovation. Courtesy photos

3 Houston innovators to know this week

Who's who

One of the cornerstones of InnovationMap is shining a spotlight on the individuals who are leading innovation in Houston, which is why we created a section dedicated to this. Our Featured Innovators section will have a Q&A with a startup owner, entrepreneur, or thought leader every week.

Another weekly article on InnovationMap that's geared toward introducing the city to prominent innovators is a roundup of who's who in the industry — not just the forces to be reckoned with in town, but people whose names you need not forget. Why? Because they've got big plans up their sleeves.

Here are this week's innovators to know, who, it just so happens, are our inaugural Featured Innovators.

Gabriella Rowe, CEO of Station Houston

Courtesy of Gabriella Rowe

It's been a winding road for Gabriella Rowe, but she's finally made it to a city she adores and in a position she says is her dream job. The New York native has worked in consulting, banking, education, tech, and more, and she has learned a lot of valuable lessons on the way.

Rowe accepted her position as CEO of Station Houston in August — a decision she says took her all of four seconds to make. The acceleration hub has a lot going on ahead of Houston's Innovation District launch, including announcing Station 3.0 in January. Read more about that — and why Rowe says wild horses couldn't drag her out of Houston —in her Featured Innovator piece.

Brian Richards, managing partner at Accenture

Courtesy of Accenture

Brian Richards is in the business of being lightyears ahead of everyone else. His job is to start thinking of solutions for tomorrow's problems, from consulting clients on innovative technologies to serving on the board of Houston Exponential.

In fact, Richards came up with the vision for Accenture's innovation hub before clients even knew they needed it. He also moved to Houston against the advice of many colleagues because he sees the potential this city has as a mecca for innovation. Read more about the hub and his career here.

Regina Vatterott, COO and co-founder of EllieGrid

Courtesy of Regina Vatterott

The idea for Regina Vatterott's smart pillbox, called EllieGrid, hit her in one fell swoop — literally. She fainted on the way to lunch and decided it was time to start taking her health seriously. She created EllieGrid shortly after and realized that medical devices don't have to be clunky or purely functional.

Now, she's got big plans to reinvent the wheel on a few other medical devices by focusing on the user experience, because, as she likes to say, people are always people first, before they are patients. Learn more about EllieGrid here.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston hospital names leading cancer scientist as new academic head

new hire

Houston Methodist Academic Institute has named cancer clinician and scientist Dr. Jenny Chang as its new executive vice president, president, CEO, and chief academic officer.

Chang was selected following a national search and will succeed Dr. H. Dirk Sostman, who will retire in February after 20 years of leadership. Chang is the director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She has been with Houston Methodist for 15 years.

Over the last five years, Chang has served as the institute’s chief clinical science officer and is credited with strengthening cancer clinical trials. Her work has focused on therapy-resistant cancer stem cells and their treatment, particularly relating to breast cancer.

Her work has generated more than $35 million in funding for Houston Methodist from organizations like the National Institutes of Health and the National Cancer Institute, according to the health care system. In 2021, Dr. Mary Neal and her husband Ron Neal, whom the cancer center is now named after, donated $25 million to support her and her team’s research on advanced cancer therapy.

In her new role, Chang will work to expand clinical and translational research and education across Houston Methodist in digital health, robotics and bioengineered therapeutics.

“Dr. Chang’s dedication to Houston Methodist is unparalleled,” Dr. Marc L. Boom, Houston Methodist president and CEO, said in a news release. “She is committed to our mission and to helping our patients, and her clinical expertise, research innovation and health care leadership make her the ideal choice for leading our academic mission into an exciting new chapter.”

Chang is a member of the American Association of Cancer Research (AACR) Stand Up to Cancer Scientific Advisory Council. She earned her medical degree from Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research. She earned her research doctorate from the University of London.

She is also a professor at Weill Cornell Medical School, which is affiliated with the Houston Methodist Academic Institute.

Texas A&M awarded $1.3M federal grant to develop clean energy tech from electronic waste

seeing green

Texas A&M University in College Station has received a nearly $1.3 million federal grant for development of clean energy technology.

The university will use the $1,280,553 grant from the U.S. Department of Energy to develop a cost-effective, sustainable method for extracting rare earth elements from electronic waste.

Rare earth elements (REEs) are a set of 17 metallic elements.

“REEs are essential components of more than 200 products, especially high-tech consumer products, such as cellular telephones, computer hard drives, electric and hybrid vehicles, and flat-screen monitors and televisions,” according to the Eos news website.

REEs also are found in defense equipment and technology such as electronic displays, guidance systems, lasers, and radar and sonar systems, says Eos.

The grant awarded to Texas A&M was among $17 million in DOE grants given to 14 projects that seek to accelerate innovation in the critical materials sector. The federal Energy Act of 2020 defines a critical material — such as aluminum, cobalt, copper, lithium, magnesium, nickel, and platinum — as a substance that faces a high risk of supply chain disruption and “serves an essential function” in the energy sector.

“DOE is helping reduce the nation’s dependence on foreign supply chains through innovative solutions that will tap domestic sources of the critical materials needed for next-generation technologies,” says U.S. Energy Secretary Jennifer Granholm. “These investments — part of our industrial strategy — will keep America’s growing manufacturing industry competitive while delivering economic benefits to communities nationwide.”

------

This article originally appeared on EnergyCapital.

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”